Overview

Mercy Health is committed to fighting cancer in all its forms, and part of that fight is investing in medical research and clinical trials to find new ways to battle the disease. By participating in our cancer treatment trials, you gain access to treatment options that are not yet widely available and you help others by contributing to advancements in cancer research. The following cancer studies are currently seeking qualified participants. If you believe you would be a strong candidate, please reach out via the contact information below:

Brain Cancer

Glioblastoma
A Phase II/III Randomized trial of Veliparib or Placebo in combination with adjuvent Temozolomide in newly diagnosed Glioblastoma with MGMT promoter Hypermethylation
Study Number: NCT02152982
Please call 419-251-4919 to learn more.

Glioma
A Phase III Randomized Double Blind Placebo Controlled Study of Armodafinil (Nuvigil) to Reduce Cancer Related Fatigue in Patients with High Grade Glioma
Study Number: NCT01781468
Please call 419-251-4919 to learn more.

Breast Cancer

Adjuvant
A Randomized, Double Blind, Parrellel Group, Placebo Controlled Multi Center Phase III Study to assess the efficacy and safety of Loaparib versus Placebo as Adjuvant Treatment in patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
Study Number: NCT02032823
Please call 419-251-4919 to learn more.

Adjuvant
A Randomized Phase III Tiral of Adjuvant Therapy Comparing Doxorubicin plus Cyclophosphamide followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High Risk Node Negative Triple Negative Invasive Breast Cancer
Study Number: NCT02488967
Please call 419-251-4919 to learn more.

Cancer Control
A Randomized Phase III trial of endocrine therapy plus entinostat/placebo in postmenopausal patients with hormone receptor positive advanced breast cancer
Study Number: NCT02115282
Please call 419-251-4919 to learn more.

Colon and Rectal Cancer

Colorectal
Randomized phase II study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF mutant Metastatic Colorectal Cancer.
Study Number: NCT02164916
Please call 419-251-4919 to learn more.

Pancreatic Cancer

Pancreas
A Phase II-R and A Phase III Trial Evaluating Both Erlotinib (PH II-R) and Chemoradiation (PH III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma
Study Number: NCT01013649
Please call 419-251-4919 to learn more.

Pancreas
A Randomized phase II study of perioperative mFOLFIRINOX versus Gemcitabine/Nab-Paclitaxel as therapy for resectable pancreatic adenocarcinoma
Study Number: NCT02562716
Please call 419-251-4919 to learn more.

Renal Cancer

Renal
Phase III Study: Everolimus for Renal Cancer Ensuing Surgical Therapy
Study Number: NCT01120249
Please call 419-251-4919 to learn more.

Prostate Cancer

Prostate
Androgen Deprivation thereapy and high dose Radiotherapy with or without whole pelvic radiothereapy in unfavorable intermediate or favorable high risk prostate cancer: A Phase III Randomized Trial
Study Number: NCT01368588
Please call 419-251-4919 to learn more.

Prostate
A Phase III trial of enzalutamide (NSC # 766085) versus enzalutamide, abiraterone and prednisone for castration resistant metastatic prostate cancer
Study Number: NCT01949337
Please call 419-251-4919 to learn more.

Prostate
A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients with Intermediate Risk Prostate Cancer
Study Number: NCT00936390
Please call 419-251-4919 to learn more.

Prostate
Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
Study Number: NCT01809691
Please call 419-251-4919 to learn more.

Bladder Cancer

Bladder
A Radnomized Phase II Study of co Expression Extrapolation (Coxen) with Neoadjuvant Chemotherapy for localized, muscle invasive bladder cancer
Study Number: NCT02177695
Please call 419-251-4919 to learn more.

Head and Neck Tumors 

Advanced Resected
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally Advanced Resected Head and Neck Cancer
Study Number: NCT00956007
Please call 419-251-4919 to learn more.

Lung Cancer

Adjuvant
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Study Number: NCT02194738
Please call 419-251-4919 to learn more.

NSCLC
A Phase III Double blind trial for surgically resected early stage non small cell lung cancer: Crizotinib versus Placebo for patients with tumors harboring the anaplastic lymphoma kinase (ALK) fusion protein
Please call 419-251-4919 to learn more.

NSCLC
Randomized double blind placebo controlled study of Erlotinib or Placebo in patients with completely resected epidermal growth factor receptor (EGFR) mutant Non Small Cell Lung Cancer (NSCLC)
Study Number: NCT02193282
Please call 419-251-4919 to learn more.

NSNSCLC
A Phase III open label randomized study of Atezolizumab (MPDL3280A Anti-PD-L1 Antibody) in combination with carboplatin + paclitaxel with or without bevacizumab compared with carboplatin + paclitaxel + bevacizumab in chemotherapy naïve patients with stage IV non squamous non-small cell lung cancer
Study Number: NCT02366143
Please call 419-251-4919 to learn more.

NSCLC
A Phase III, Open label, Multicenter, randomized study evaluating the efficacy and safety of Atezolizumab (MPDL3280A Anti-PD-L1 Antibody) in combination with caroplatin +paclitaxel or Atexolizumab in combination with Carboplatin + Nab Paclitaxel versus carboplatin + Nab Paclitaxel in chemotherapy naive patients with Stage IV Squamous non small cell lung cancer
Study Number: NCT02367794
Please call 419-251-4919 to learn more.

Melanoma/Sarcoma

Patient Satisfaction
Assessment of Patient Satisfaction with Participation in Phase II/III NCCTG Clinical Trials
Cancer Control Prevention
A Cohort Study to Evaluate Genetic Predictors for Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
Study Number: NCT01824836
Please call 419-251-4919 to learn more.

If you believe that you would be a strong candidate for one of our cancer clinical trials, please reach out to the contacts listed above. Participating in medical trials gives you access to new or emerging treatment options that are not yet widely available, and allows you to help push medical research forward in the process.

Why Choose Mercy Health?
Mercy Health physicians and healthcare professionals are conducting medical research to help patients live healthier and longer. They are committed to making lives better—mind, body and spirit.